BusinessSun Pharma Licenses LDL-C Drug Lerodalcibep from LIB Therapeutics
Sun Pharmaceutical Industries has signed an exclusive licensing agreement with LIB Therapeutics Inc to commercialize and manufacture lerodalcibep worldwide, excluding the U.S. and China. Lerodalcibep, approved in the EU as Lyrokaul and in the U.S. as Lerochol, treats hypercholesterolemia by reducing LDL cholesterol. The PCSK9 inhibitor market outside the U.S. and China reached $3.7 billion by Q2 2026, growing at a 38% CAGR.
Hindu Business·3h ago·Hyderabad




